Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APTO
CUSIPN/A
Phone64-7479-9828
Debt
Debt-to-Equity RatioN/A
Current Ratio7.51
Quick Ratio7.51
Price-To-Earnings
Trailing P/E Ratio-6.17
Forward P/E Ratio-3.65
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.39 per share
Price / Book8.23
Profitability
EPS (Most Recent Fiscal Year)($0.52)
Net Income$-11,660,000.00
Net MarginsN/A
Return on Equity-136.61%
Return on Assets-119.69%
Miscellaneous
Employees20
Outstanding Shares33,410,000
Market Cap$107.26
Aptose Biosciences (NASDAQ:APTO) Frequently Asked Questions
What is Aptose Biosciences' stock symbol?
Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."
How were Aptose Biosciences' earnings last quarter?
Aptose Biosciences Inc. (NASDAQ:APTO) posted its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.23) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.11. View Aptose Biosciences' Earnings History.
What price target have analysts set for APTO?
3 brokers have issued 12 month target prices for Aptose Biosciences' shares. Their forecasts range from $6.00 to $8.50. On average, they expect Aptose Biosciences' share price to reach $7.1667 in the next twelve months. This suggests a possible upside of 123.3% from the stock's current price. View Analyst Ratings for Aptose Biosciences.
What is the consensus analysts' recommendation for Aptose Biosciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Aptose Biosciences stock?
Here are some recent quotes from research analysts about Aptose Biosciences stock:
- 1. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating and are increasing our price target to $8.50 from $6. The drivers to our valuation change include: (1) adjustment to base year; (2) adjustment to fully diluted share count (negative impact, but no warrants, preferred shares, or debt); (3) adjusting our projected launch year for 2028 based on visibility of clinical hold lifting; and (4) increasing our projected chances of success for to 25%." (6/29/2018)
- 2. According to Zacks Investment Research, "Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. " (5/16/2018)
Who are some of Aptose Biosciences' key competitors?
Some companies that are related to Aptose Biosciences include PDL BioPharma (PDLI), NanoString Technologies (NSTG), Scholar Rock (SRRK), Osiris Therapeutics (OSIR), Cellular Biomedicine Group (CBMG), Vericel (VCEL), Neon Therapeutics (NTGN), Adverum Biotechnologies (ADVM), MeiraGTx (MGTX), Jounce Therapeutics (JNCE), Nantkwest (NK), Allena Pharmaceuticals (ALNA), Agenus (AGEN), Idera Pharmaceuticals (IDRA) and ADMA Biologics (ADMA).
Who are Aptose Biosciences' key executives?
Aptose Biosciences' management team includes the folowing people:
- Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)
- Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)
- Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical Operations
- Dr. Stephen B. Howell, Chief Medical Officer (Age 73)
- Mr. Peter Murray, Director of Clinical Devel.
Has Aptose Biosciences been receiving favorable news coverage?
Press coverage about APTO stock has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aptose Biosciences earned a media sentiment score of 0.05 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 43.00 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of Aptose Biosciences?
Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aptose Biosciences' stock price today?
One share of APTO stock can currently be purchased for approximately $3.21.
How big of a company is Aptose Biosciences?
Aptose Biosciences has a market capitalization of $107.26 million. The biotechnology company earns $-11,660,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Aptose Biosciences employs 20 workers across the globe.
How can I contact Aptose Biosciences?
Aptose Biosciences' mailing address is 5955 AIRPORT ROAD SUITE 228, MISSISSAUGA A6, L4V 1R9. The biotechnology company can be reached via phone at 64-7479-9828 or via email at [email protected]
MarketBeat Community Rating for Aptose Biosciences (NASDAQ APTO)
MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote "Outperform" if you believe APTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APTO will underperform the S&P 500 over the long term. You may vote once every thirty days.
